Developing A Class Of Newly Discovered T-cells To Make Cell Therapies More Durable, Longer-lasting and Safer For Patients
RORABio is developing a first-in-class T-cell platform for targeting indications across cancer and infectious diseases. The platform consists of a newly discovered, long-lived, stem-like memory cell population that we call “RORA-Tscm”. Since presence of RORA-Tscm cells correlates with reduced tumor burdens in animal models and is emerging as a hallmark of better clinical outcomes for some patients, we are developing these cells in two formats: 1) modified with a mono- or bispecific chimeric receptor antigen (CAR) to make new CAR-T drugs with potential to be more durable, safer and long-lasting, and 2) as a stand-alone therapy to reconstitute the immune system of HIV infected patients.
Proprietary
Manufacturing Process
RORA-Tscm cells can be scalably expanded to homogeneity under GLP- and GMP-grade like conditions
Superior Stem-ness
and Durability
RORA-Tscm cells are associated with positive clinical outcomes in patients
Flexible T-cell Platform For Making New Cell Therapies
RORA-Tscm cells can be used alone or for making genetically engineered biologics (e.g., expressing a CAR or edited/deleted gene)
LATEST NEWS
October 10, 2023
NIH will host a meeting entitled Strategies For An HIV Cure 2023 from October 12-13, 2023. The meeting will feature presentations from ten NIH Martin Delaney Collaboratories for HIV Cure Research. The event will also include presentations from the two Centers for Innovative HIV/AIDS Vaccine and Cure Research (CIAVCR). It will also feature abstract-driven poster sessions. Our Chief Scientific Officer, Dr. Rafick Sekaly, and our VP Clinical Opps, Dr. Ashish Sharma, will be attending and presenting at the meeting.
For more information